Physician profile
Stephen Kirk
NPI 1578737979
$1,510.97
in general payments reported to CMS, 2019-2025
23 companies · $358 in 2025
The $358 reported for 2025 was more than what 79% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.64 · 2020: $61.14 · 2021: $294 · 2022: $158 · 2023: $249 · 2024: $334 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $222.60 | 2020-2021 | |
| Trice Medical, INC. | $182.56 | 2022-2025 | |
| Boston Scientific Corporation | $128.70 | 2021-2025 | Artisan |
| Bioventus LLC | $104.52 | 2019-2024 | Exogen Ultrasound Bone Healing System, Durolane, Exogen Ultrasound Bone Healing System |
| Stryker Corporation | $101.41 | 2023-2025 | Triathlon, Aequalis Perform Reversed |
| Depuy Synthes Sales INC. | $98.65 | 2019-2024 | Monovisc |
| Endo Pharmaceuticals INC. | $94.04 | 2020-2024 | Xiaflex |
| Anika Therapeutics, INC. | $74.61 | 2021-2023 | Ovomotion |
| Resmed Corp | $73.01 | 2024 | |
| Ferring Pharmaceuticals INC. | $56.18 | 2020-2024 | Euflexxa |
| Endo USA, INC. | $54.65 | 2024-2025 | Xiaflex |
| Avanos Medical | $53.95 | 2023-2024 | On-Q* Pump and Accessories |
| Solventum Corporation | $44.53 | 2024-2025 | Prevena, Prevena Restor Axioform |
| Amgen INC. | $35.46 | 2021-2025 | Krystexxa |
| Vertex Pharmaceuticals Incorporated | $32.57 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $28.41 | 2025 | Maci |
| Nevro Corp. | $25.40 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $21.22 | 2023 | Zilretta, Iovera, Exparel |
| Fidia Pharma USA INC. | $18.12 | 2019 | |
| Hydrocision, INC. | $16.68 | 2025 | Tenjet |
| Innovation Technologies INC | $16.64 | 2024 | Irrisept |
| Pfizer INC. | $14.45 | 2021 | |
| Spr Therapeutics, INC | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.